Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutiv

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and effica

Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensu

On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cyt

2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be be

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores rela

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial

Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus

Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1

Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell ratin

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with l

Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus

Scotiabank analyst Greg Harrison maintains Geron (NASDAQ:GERN) with a Sector Outperform and lower

Stifel analyst Stephen Willey maintains Geron (NASDAQ:GERN) with a Buy and lowers the price targe

Barclays analyst Peter Lawson maintains Geron (NASDAQ:GERN) with a Overweight and lowers the pric

Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and lowers the price target fro

Geron (NASDAQ:GERN) reported quarterly losses of $(0.04) per share which beat the analyst consensus

B. Riley Securities analyst Kalpit Patel maintains Geron (NASDAQ:GERN) with a Buy and lowers the

Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and raises the price target fro

Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency

In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK pro

HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) with a Buy and mainta

Geron received $250 million in gross proceeds at closing, with access to an additional $125 million

Geron (NASDAQ:GERN) reported quarterly losses of $(0.04) per share which beat the analyst consensus

HC Wainwright & Co. analyst Emily Bodnar reiterates Geron (NASDAQ:GERN) with a Buy and mainta